Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

ATP Modulates Noradrenaline Release by Activation of Inhibitory P2Y Receptors and Facilitatory P2X Receptors in the Rat Vas Deferens

Glória Queiroz, Carlos Talaia and Jorge Gonçalves
Journal of Pharmacology and Experimental Therapeutics November 2003, 307 (2) 809-815; DOI: https://doi.org/10.1124/jpet.103.054809
Glória Queiroz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carlos Talaia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorge Gonçalves
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The role of ATP on the modulation of noradrenaline release elicited by electrical stimulation (100 pulses/8 Hz) was studied in the prostatic portion of rat vas deferens preincubated with [3H]noradrenaline. In the presence of P1 antagonists, the nucleotides 2-methylthioadenosine-5′-triphosphate (2-MeSATP), 2-methylthioadenosine 5′-diphosphate (2-MeSADP), ADP, and ATP decreased electrically evoked tritium overflow up to 44%, with the following order of potency: 2-MeSATP > 2-MeSADP > ADP ≥ ATP. The P2Y antagonists reactive blue 2 (RB2) and 2-methylthioadenosine 5′-monophosphate (2-MeSAMP) increased, whereas the P2X antagonist pyridoxal-5′-phosphate-6-(2′-naphthylazo-6′-nitro-4′,8′-disulfonate) (PPNDS) decreased evoked tritium overflow. The inhibitory effect of 2-MeSATP was antagonized by RB2 (10 μM) and by 2-MeSAMP (10 μM) but not by the selective P2Y1 receptor antagonist 2′-deoxy-N6-methyladenosine 3′,5′-bisphosphate (MRS 2179; 10 μM). When, besides P1 receptors, inhibitory P2Y receptors were blocked with RB2, α,β-methyleneadenosine 5′-triphosphate (α,β-meATP), β,γ-imidoadenosine 5′-triphosphate (β,γ-imidoATP), β,γ-methyleneadenosine 5′-triphosphate (β,γ-meATP), 2-MeSATP, and ATP enhanced tritium overflow up to 140%, with the following order of potency: α,β-meATP > 2-MeSATP = ATP = β,γ-meATP ≥ β,γ-imidoATP. The facilitatory effects of α,β-MeATP and β,γ-imidoATP were prevented by PPNDS. Under the same conditions, apyrase attenuated, whereas the ectonucleotidase inhibitor 6-N,N-diethyl-d-β,γ-dibromomethylene 5′-triphosphate enhanced tritium overflow, an effect that was prevented by PPNDS. In the prostatic portion of the rat vas deferens, endogenous ATP exerts a dual and opposite modulation of noradrenaline release: an inhibition through activation of P2Y receptors with a pharmacological profile similar to that of the P2Y12 and P2Y13 receptors and a facilitation through activation of P2X receptors with a pharmacological profile similar to that of P2X1 and P2X3, or PX2/P2X3 receptors.

Footnotes

  • This work was supported by FCT (I&D no. 226/94, POCTI-QCAIII, and FEDER) and POCTI/36545/FCB/2000.

  • DOI: 10.1124/jpet.103.054809.

  • ABBREVIATIONS: 2-MeSATP, 2-methylthioadenosine-5′-triphosphate; 2-MeSADP, 2-methylthioadenosine-5′-diphosphate; RB2, reactive blue 2; 2-MeSAMP, 2-methylthioadenosine 5′-monophosphate; MRS 2179, 2′-deoxy-N6-methyladenosine 3′,5′-bisphosphate; α,β-meATP, α,β-methyleneadenosine 5′-triphosphate; β,γ-imidoATP, β,γ-imidoadenosine 5′-triphosphate; β,γ-meATP, β,γ-methyleneadenosine 5′-triphosphate; PPNDS, pyridoxal-5′-phosphate-6-(2′-naphthylazo-6′-nitro-4′,8′-disulphonate); DPCPX, 8-cyclopentyl-1,3-dipropylxanthine; ZM 241385, 4-(2[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)-phenol; NF 279, 8,8′-[carbonylbis(imino-4,1-phenylenecarbonylimino-4,1-phenylenecarbonylimino)]bis-1,3,5-naphthalenetrisulfonic acid; ARL 67156, 6-N,N-diethyl-d-β,γ-dibromomethylene 5′-triphosphate; PPADS, pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid.

    • Received May 21, 2003.
    • Accepted July 10, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 307 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 307, Issue 2
1 Nov 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
ATP Modulates Noradrenaline Release by Activation of Inhibitory P2Y Receptors and Facilitatory P2X Receptors in the Rat Vas Deferens
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

ATP Modulates Noradrenaline Release by Activation of Inhibitory P2Y Receptors and Facilitatory P2X Receptors in the Rat Vas Deferens

Glória Queiroz, Carlos Talaia and Jorge Gonçalves
Journal of Pharmacology and Experimental Therapeutics November 1, 2003, 307 (2) 809-815; DOI: https://doi.org/10.1124/jpet.103.054809

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleNEUROPHARMACOLOGY

ATP Modulates Noradrenaline Release by Activation of Inhibitory P2Y Receptors and Facilitatory P2X Receptors in the Rat Vas Deferens

Glória Queiroz, Carlos Talaia and Jorge Gonçalves
Journal of Pharmacology and Experimental Therapeutics November 1, 2003, 307 (2) 809-815; DOI: https://doi.org/10.1124/jpet.103.054809
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CVN424, a novel GPR6 inverse agonist for Parkinson's disease
  • Methylone Brain Concentrations and Pharmacodynamic Effects
  • Oxysterols and Ethanol
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics